Theravance Biopharma Inc

TBPH

Add to Watchlist

16.220USD

-0.290-1.76%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

Theravance Biopharma Inc's Score

Industry at a Glance

Industry Ranking

42 / 155

Overall Ranking

115 / 4482

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Theravance Biopharma Inc Highlights

StrengthsRisks

Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development and commercialization of medicines for the specialty respiratory and neurologic diseases. The Company operates through a single segment, namely, development and commercialization of human therapeutics. Its product, YUPELRI (revefenacin) inhalation solution, is a nebulized long-acting muscarinic antagonist used for the treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in the lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Its Ampreloxetine, is a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 87.14% year-on-year.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Overvalued

The company’s latest PE is 7.11, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 53.21M shares, decreasing 5.81% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 4.07K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.05.

Analyst Rating

Based on 6 analysts

Buy

Current Rating

17.200

Target Price

+4.18%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Theravance Biopharma Inc is 8.37, ranking 61 out of 155 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 17.70M, representing a year-over-year increase of 15.02%, while its net profit experienced a year-over-year increase of 63.67%.

Score

Industry at a Glance

Previous score

8.37

Change

0



Financials

9.25

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

5.34

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.70

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.54

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Theravance Biopharma Inc is 7.25, ranking 83 out of 155 in the Pharmaceuticals industry. Its current P/E ratio is 7.11, which is 748.92% below the recent high of 60.35 and 356.57% above the recent low of -18.24.

Score

Industry at a Glance

Previous score

7.25

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 42/155

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Theravance Biopharma Inc is 7.33, ranking 103 out of 155 in the Pharmaceuticals industry. The average price target is 27.00, with a high of 42.00 and a low of 13.00.

Score

Industry at a Glance

Previous score

7.33

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Theravance Biopharma Inc is 6.51, ranking 109 out of 155 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 16.88 and the support level at 15.85, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.98

Change

-0.47

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Theravance Biopharma Inc is 10.00, ranking 1 out of 155 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 103.22%, representing a quarter-over-quarter increase of 4.82%. The largest institutional shareholder is Invesco, holding a total of 391.87K shares, representing 0.76% of shares outstanding, with 5702.29% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Madison Avenue Partners LP

9.51M

--

Weiss Asset Management

7.46M

--

Newtyn Management, LLC

4.30M

-13.13%

BlackRock Institutional Trust Company, N.A.

3.25M

+0.67%

Irenic Capital Management LP

2.76M

--

Winningham (Rick E)

1.15M

-6.12%

D. E. Shaw & Co., L.P.

1.26M

+4.19%

Acadian Asset Management LLC

1.17M

+7.03%

State Street Investment Management (US)

1.10M

+4.36%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Theravance Biopharma Inc is 6.12, ranking 59 out of 155 in the Pharmaceuticals industry. The company's beta value is 0.18. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Theravance Biopharma Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Theravance Biopharma Inc

TBPH

7.56 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Catalyst Pharmaceuticals Inc

CPRX

9.11 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Jazz Pharmaceuticals PLC

JAZZ

8.81 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Royalty Pharma PLC

RPRX

8.72 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Kiniksa Pharmaceuticals International PLC

KNSA

8.59 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Neurocrine Biosciences Inc

NBIX

8.52 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment